1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - The Hong Kong innovative drug sector's valuation has not reached its peak and is below the 50% quantile. The industry is in a high - prosperity stage with improving performance in innovative drugs and CXO [1][11] - The innovative drug industry is entering a recovery phase in 2025, driven by industry trends, policies, and events. BD licensing of Chinese innovative drugs overseas is booming, indicating international recognition [2] - The Hong Kong Innovative Drug ETF (513120.OF) has advantages such as good liquidity, high - purity composition, and convenient trading, making it a good investment tool [4] 3. Summary by Directory 3.1 Value Analysis - **Valuation Level**: The PE of the China Securities Hong Kong Innovative Drug Index on August 8, 2025, was 45.73, below the 50% quantile (47.42x), indicating that the valuation of the Hong Kong innovative drug sector has not reached its peak [9] - **Performance Improvement**: The performance of innovative drugs (Biotech + Pharma) and CXO is improving. After ten batches of centralized procurement, innovative drug varieties of Pharma companies are becoming the main growth force, and leading biotech companies' products are rapidly expanding. CXO's performance is also rebounding due to the high - prosperity of the innovative drug track [11][13] - **Representative Companies**: Companies like BeiGene, Kelun Botai, and others have strong R & D capabilities, rich pipelines, and successful international cooperation experiences [20][23] - **Comparison between H - shares and A - shares**: H - shares have a larger scale, higher revenue, more listed Biotech companies, and lower valuations than A - shares. The proportion of innovative drugs in H - shares is also higher [36][39] 3.2 Industry Analysis - **Development Stages**: From 2015 - 2025, the innovative drug industry has gone through preliminary exploration (2015 - 2018), capital boom (2019 - 2021), deep adjustment (2022 - 2024), and recovery (2025) stages [2] - **Policy Support**: Policies have evolved from governance system innovation to continuous optimization and national - level support. Domestic policies have accelerated the approval process and improved the commercialization of innovative drugs through measures like optimizing the review and approval process and promoting医保access [2][60] - **Ecosystem Features**: The 18A channel in Hong Kong provides financing for unprofitable biotech companies. Overseas cooperation has led to the re - evaluation of innovative drug companies' valuations, with increasing cooperation between Chinese and international pharmaceutical giants [76][80] - **Internationalization Potential**: China has achieved breakthroughs in the quantity, quality, and technology of innovative drugs. The number of self - developed innovative drugs ranks first globally, the proportion of FIC molecules ranks second, and the gap in drug listing time between China and foreign countries has been significantly shortened [88][90][92] 3.3 ETF Product Introduction - **ETF General Information**: The GF China Securities Hong Kong Innovative Drug ETF was established on July 1, 2022, tracking the China Securities Hong Kong Innovative Drug Index. It has good liquidity, with a fund scale of 16.76 billion yuan as of August 6, 2025, and its daily trading volume has increased significantly [99] - **Features and Advantages**: It has high - purity industry focus and concentration, with the weight of bioproducts and chemical pharmaceuticals in the index reaching 92.5%, and the top ten component stocks' concentration reaching 70.59%. The industry is in a period of intensive realization, and policies provide full - chain support [105][106] - **Configuration Attributes**: It is an efficient tool for investors to allocate to the Hong Kong Biotech track, helping to avoid individual stock R & D risks. It also has medium - to - long - term rotation allocation value, with the index's one - year return ranking first among QDII stock funds and significant south - bound capital inflows [107][108]

Core Viewpoint - The pharmaceutical and biotechnology sectors have seen significant gains recently, driven by supportive policies and strong performance from leading CXO companies, indicating a potential turning point for the sector's earnings [1] Group 1: ETF Performance - The Innovation Drug ETF (517110) rose over 3.2%, the Biopharmaceutical ETF (512290) increased by more than 2.2%, the Medical ETF (159828) gained over 1.3%, and the Vaccine ETF (159643) saw an increase of over 1.0% [1] - The Innovation Drug ETF tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in the research and production of innovative drugs, reflecting the overall performance of companies with research capabilities and growth potential [1] Group 2: Policy and Market Trends - Recent policies, including measures to support the high-quality development of innovative drugs and the 11th batch of centralized procurement notifications, are significant for the pharmaceutical and medical device sectors [1] - The performance of leading CXO companies that have disclosed their earnings has shown a recovery trend, suggesting that the earnings turning point for the sector may be approaching [1] Group 3: Index Descriptions - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which includes companies in biotechnology, pharmaceuticals, and medical devices, focusing on high-growth and strong R&D capabilities [2] - The Medical ETF (159828) follows the CSI Medical Index (399989), which represents companies in medical devices, services, and biopharmaceuticals, serving as an important benchmark for investment value in the domestic medical industry [2] - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), focusing on companies involved in vaccine research, production, and related industries, highlighting significant growth and specialization [2]

Group 1 - The pharmaceutical and biotechnology sector has seen significant growth recently, driven by continuous policy support and the ongoing performance of innovative drugs and CXO companies [1] - The introduction of measures to support the high-quality development of innovative drugs and the 11th batch of centralized procurement notifications are crucial for the pharmaceutical and medical device sectors [1] - WuXi AppTec's net profit attributable to the parent company increased by 101.92% year-on-year, indicating a potential turning point for the sector's performance [1] Group 2 - The medical device sector benefited from optimized centralized procurement rules, with exports of medical instruments and devices increasing by 5.2% year-on-year in June, while imports rose by 9.1% [1] - Policies supporting innovative drugs span the entire chain from research and development to market access and payment, with ongoing progress in the commercial insurance innovative drug catalog [1] - The Guotai ChiNext Medical ETF (159377) tracks the ChiNext Medical Index (399275), which can experience daily fluctuations of up to 20%, reflecting the overall performance of listed companies in the biopharmaceutical, medical device, and healthcare service sectors [1]

Core Insights - The pharmaceutical and biotechnology sector has seen significant growth recently, driven by ongoing trends in innovative drugs and CXO markets [1] - Recent policies, including measures to support high-quality development of innovative drugs and notifications regarding the 11th batch of national drug centralized procurement, are crucial for the pharmaceutical and medical device sectors [1] - CXO leading companies that have disclosed their performance show a positive recovery trend, indicating a potential turning point for the sector's performance [1] Policy Developments - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" and the notification on the 11th batch of centralized procurement are significant for the pharmaceutical and medical device sectors [1] - The ongoing centralized procurement process is expected to benefit pharmaceutical and medical device companies that adapt to the optimized procurement rules [1] Market Performance - The CXO sector has experienced substantial growth this month, attributed to improved overseas demand and a gradual recovery in orders [1] - The innovative drug policy support window is seen as an opportunity for investors, with a focus on the progress of commercial insurance innovative drug catalog and companies with better-than-expected semi-annual report performances [1] Investment Opportunities - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which can fluctuate by up to 20% in a single day [1] - The index focuses on representative new drug research and development companies in the technology innovation field, emphasizing high R&D investment and innovation capabilities [1]

Core Viewpoint - The news highlights the significant developments in the innovative pharmaceutical sector, particularly focusing on Fosun Pharma's recent licensing agreement and the broader trends in AI-driven drug discovery and CAR-T therapies. Group 1: Fosun Pharma's Licensing Agreement - Fosun Pharma signed a licensing agreement with Expedition for the small molecule inhibitor XH-S004, with a potential total value of $645 million (over 4.6 billion RMB) [2][3] - The agreement allows Expedition to develop, produce, and commercialize XH-S004 outside of China, while Fosun retains rights for the Chinese market [2][3] - XH-S004 is currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and Phase Ib for chronic obstructive pulmonary disease in China, with a cumulative R&D investment of approximately 72 million RMB as of August 11 [2][4] Group 2: Competitive Landscape - The leading competitor in the small molecule inhibitor space is Insmed's Brensocatib, which is under FDA review and may become the first approved treatment for bronchiectasis [4] - Other domestic companies, such as Haikang and Hengrui, are also advancing in this area, with Haikang securing a significant licensing deal worth up to $4.62 million [4] Group 3: AI Drug Discovery - Fosun Pharma is actively involved in AI drug discovery, having partnered with AI pharmaceutical company Insilico Medicine since 2022 to develop AI-targeted drugs [5] - The company has also engaged in strategic collaborations with DeepMind Technology to explore antibody drug development using AI and physical modeling [5] Group 4: CAR-T Therapy Developments - Fosun Pharma is recognized for its CAR-T therapy pipeline, with the CARVYKTI therapy achieving sales of $439 million in Q2 2025, indicating strong market potential [6] - The pricing of CAR-T therapies remains a challenge, with costs exceeding 999,000 to 1,290,000 RMB, which limits access to insurance coverage [6] - The evolving payment landscape for CAR-T therapies is expected to improve as generic technologies mature and more products enter the market, potentially lowering costs [6] Group 5: Market Outlook - The innovative drug sector is anticipated to remain active, with significant upcoming international pharmaceutical conferences and discussions on insurance drug lists expected to drive interest [7] - The domestic innovative drug market is likely to benefit from increased clinical data releases and a rebound in funding for new drug development [7] - Investors are encouraged to consider the innovative drug ETF (159622) for exposure to leading companies in the sector, with a diversified portfolio comprising 40% Hong Kong stocks and 60% A-shares [7]

Core Viewpoint - The Ministry of Industry and Information Technology, along with six other departments, has issued an implementation opinion to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for key technological breakthroughs by 2027 and establishing an advanced technical, industrial, and standard system for the sector [1] Group 1: Industry Development - Brain-computer interfaces are identified as a critical sector that integrates cutting-edge neuroscience and information technology, with applications spanning medical detection, disease screening, and drug treatment [1] - The clinical advancement of brain-computer interfaces is accelerating, with significant potential for commercialization once the relevant technologies are mature and approved for clinical use [1] Group 2: Investment Opportunities - Xiangcai Securities highlights that the weight of brain-computer interfaces in the medical device ETF (562600) is as high as 22.72%, ranking it among the top in the entire market [1] - The recently listed Hong Kong Stock Connect medical ETF (520510) provides investors with more opportunities to allocate resources in sub-sectors such as AI healthcare and CXO [1]

Group 1 - The Hong Kong stock market indices collectively rose on August 7, with mixed performance in tech stocks, while Apple-related stocks led the gains [1] - The newly listed Hong Kong Stock Connect Medical ETF (520510) experienced fluctuations, dropping over 1% at one point, with most holdings declining [1] - The report from Minyin International highlighted that domestic medical insurance policies and overseas value recognition will support the ongoing trend in China's innovative drug market [1] Group 2 - The Hong Kong Stock Connect Medical ETF (520510) tracks the Hong Kong Stock Connect Medical Theme Index, covering three major segments of the medical sector, with over 30% weight in CXO, over 20% in AI medical, and nearly 50% in innovative drugs [2] - The ETF was launched on the Shanghai Stock Exchange and supports T+0 trading [2]

Core Insights - The pharmaceutical and biotechnology sector has recently experienced significant growth, driven by ongoing trends in innovative drugs and CXO markets, with continuous catalysts emerging [1] - Recent policies, including the "Several Measures to Support the High-Quality Development of Innovative Drugs" and notifications regarding the 11th batch of centralized procurement, are crucial for the pharmaceutical and medical device sectors [1] - The innovative drug policy supports development across the entire chain from research and development to market access and payment, while the 11th batch of centralized procurement emphasizes principles such as "stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition" [1] - The sector is showing signs of recovery, with a potential inflection point in performance on the horizon, and investment opportunities arising from the optimization of centralized procurement rules in the medical device sector [1] Industry Overview - The Medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies involved in medical devices, medical services, and biopharmaceuticals from the Shanghai and Shenzhen markets to reflect the overall performance of the medical industry [1] - The CSI Medical Index focuses on the healthcare sector and covers representative enterprises within the industry, effectively reflecting market characteristics and development trends [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Link A (012634) and Guotai CSI Medical ETF Link C (012635) [1]

Group 1 - Lepu Biopharma announced its first profit in H1 2025, with profits expected to be no less than 24 million yuan, compared to a loss of 197 million yuan in the previous period, making it one of the few Hong Kong-listed innovative drug companies to achieve breakeven [1] - Industry leader BeiGene reported an H1 operating profit of 799 million yuan and a net profit attributable to shareholders of 450 million yuan, marking its first half-year profitability [1] - The National Healthcare Security Administration has emphasized "anti-involution," indicating that the lowest price will no longer be the benchmark for centralized procurement, and innovative drugs will not be included in centralized procurement [1] Group 2 - The commercial health insurance adjustment for innovative drug catalogs officially started in early July, which is expected to further expand the payment space for innovative drugs [1] - The Hong Kong Stock Connect Medical ETF (520510) was launched on the Shanghai Stock Exchange, supporting T+0 trading and filling a gap in the Hong Kong Stock Connect medical sector, providing investors with more options in CXO, innovative drugs, and AI medical fields [1]

Market Overview - In July 2025, all major A-share indices rose, with the ChiNext Index showing the highest increase of 8.14% and the Shanghai 50 Index the lowest at 2.36% [2] - The total margin balance in the Shanghai and Shenzhen markets reached 1,978.497 billion yuan, an increase of 133.858 billion yuan from the previous month [2] Company Research: Zhongchong Co., Ltd. (002891) - In the first half of 2025, Zhongchong Co., Ltd. reported revenue of 2.432 billion yuan, a year-on-year increase of 24.32%, and a net profit of 203 million yuan, up 42.56% [14] - The company has made significant progress in its overseas business, achieving revenue of 1.575 billion yuan from international markets, a growth of 17.61% [14] - The pet food segment, particularly the staple food category, saw substantial growth, with revenue reaching 783 million yuan, a remarkable increase of 85.79% [15] Industry Research: Pharmaceutical and Biological Sector - The pharmaceutical and biological sector experienced a significant increase of 13.93% in July 2025, driven by innovative drugs and CXO segments [5] - Key policies supporting the high-quality development of innovative drugs were introduced, which are expected to positively impact the pharmaceutical and medical device sectors [4] - The cumulative revenue of the pharmaceutical manufacturing industry for the first half of 2025 was 1,227.52 billion yuan, reflecting a year-on-year decline of 1.2% [4] Industry Research: Machinery Equipment Sector - The machinery equipment sector outperformed the market with a 9.82% increase from July 6 to August 5, 2025 [7] - The sales of excavators in the first half of 2025 showed a growth rate exceeding 20%, indicating strong domestic demand [7] - The upcoming World Robot Conference is expected to catalyze investment opportunities in humanoid robots [8] Industry Research: Metals Sector - The steel market is expected to experience limited upward momentum due to recent price adjustments, with short-term prices likely to fluctuate [10] - Copper prices are supported by tight supply despite recent adjustments due to U.S. tariffs [10] - The aluminum market may see price increases if actual inventory demand performs well in the upcoming months [11]